+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The prognostic significance of increasing marker levels in metastatic breast cancer patients with clinically complete remission, partial remission or stable disease



The prognostic significance of increasing marker levels in metastatic breast cancer patients with clinically complete remission, partial remission or stable disease



International Journal of Biological Markers 13(1): 10-15



TPS, CA 15-3 and CEA were determined in metastatic breast cancer patients during treatment. After six months of follow-up the patients were divided into four groups according to the UICC criteria for treatment response. Forty-six patients with a more favorable prognosis (complete remission, partial remission or stable disease) were followed for an extended period. In 30 of the 46 patients at least one marker had increased at the end of the six-month period by at least 25% (TPS in 54%, CA 15-3 in 20%, CEA in 20%). All these 30 patients subsequently developed progression. The prognostic sensitivity was 83%, 30% and 30%, respectively, for TPS, CA 15-3 and CEA. The combination of TPS and CA 15-3 showed a sensitivity of 96%. The median lead time was about 8 months for TPS and CA 15-3, but less than 50% of the patients showed a lead time for CA 15-3 as compared to TPS. We conclude that TPS and CA 15-3 determinations are helpful for the prediction of progression during the follow-up of breast cancer patients.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 009611183

Download citation: RISBibTeXText

PMID: 9681294


Related references

The significance of increasing marker levels in metastatic breast cancer patients with clinically complete remission, partial remission or stable disease during therapy monitoring. Anticancer Research 18(6C): 4856, 1998

Increasing marker levels in metastatic breast cancer patients with clinically complete remission. Tumor Biology 18(SUPPL 2): 41, Sept, 1997

Remission and survival data of metastatic breast cancer patients achieving complete remission with combination chemo immuno therapy. Clinical Research 26(3): 438A, 1978

Disease-free interval in metastatic breast cancer patients undergoing complete remission: implications of cross-sectional study design and biologic considerations about disease history. Breast Cancer 24(3): 491-492, 2017

Does longer disease-free interval affect the complete remission in metastatic breast cancer?. Breast Cancer 24(3): 490, 2017

A durable complete remission between two isolated presentations of metastatic breast cancer, the second with intracardiac disease. Clinical Breast Cancer 7(2): 162-163, 2006

Clinical characteristics of patients with metastatic breast cancer with complete remission following systemic treatment. Japanese Journal of Clinical Oncology 28(6): 368-373, 1998

How long should we maintain anti-HER2 therapy for metastatic breast cancer patients with complete remission?. Future Oncology 11(20): 2799-2801, 2016

Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. Journal of Clinical Oncology 14(8): 2197-2205, 1996

Incidence and prognostic significance of idiopathic thrombocytopenic purpura in patients with Hodgkin's disease in complete hematological remission. Haematologica 83(7): 669-670, 1998

High-dose therapy and autologous stem cell transplantation as consolidation therapy during first complete remission or partial remission in patients with unfavorable prognosis and advanced stage Hodgkins disease. Blood 90(10 SUPPL 1 PART 1): 114A, Nov 15, 1997

Autologous bone marrow transplantation abmt for metastatic breast carcinoma mbc in complete or partial remission cr or pr. Breast Cancer Research & Treatment 14(1): 147, 1989

Cost effectiveness of positron emission tomography in patients with Hodgkin's lymphoma in unconfirmed complete remission or partial remission after first-line therapy. Journal of Clinical Oncology 28(8): 1415-1421, 2010

Improved remission rates and remission duration in young women with metastatic breast cancer following combined oophorectomy and chemotherapy: a study of Cancer and Leukemia Groupe B. Cancer 43(6): 2215-2222, 1979

Trastuzumab in metastatic breast cancer after complete remission: How long is enough?. Medical Oncology 32(8): 211, 2016